# ACCESS2 Stakeholder Walkthrough Feedback And Go/No-Go Note

## Purpose

This note records the first stakeholder walkthrough feedback checkpoint for the current ACCESS2 demo package. It is a documentation record only. It does not approve production mutation, staging mutation, Railway mutation, new runtime behavior, or architecture changes.

## Walkthrough Record

- Walkthrough date: May 18, 2026.
- Walkthrough version: v1.
- Audience/stakeholder type: initial stakeholder walkthrough; specific stakeholder role was not separately recorded.
- Supporting screen prints: `ACCESS2_walkthrough_1.gdoc`.

## What Was Demonstrated

- The ACCESS2 stakeholder walkthrough v1 script was executed.
- The walkthrough used the current demo package and printable walkthrough guide.
- The demonstrated story remained within the current release posture:
  - V1 production is a read-only demo.
  - V2 correction-loop mutation remains localhost-only.
  - Staging mutation remains deferred until isolated staging or preview infrastructure is explicitly approved.

## What Landed Well

- The walkthrough completed and everything looked good.
- No specific UI, copy, workflow, or proof-chain issues were reported.

## What Caused Confusion

- No concrete confusion was reported.
- Context note: this was net-new for the audience, and no one had a prior expectation for what the UI should look like.

## Objections Or Risks Raised

- No objections were reported.
- No new risks were raised.

## Follow-Up Questions

- No follow-up questions were recorded.

## Go/No-Go Recommendation

Recommendation: go for continued stakeholder walkthrough use of the current ACCESS2 demo package in its existing safety posture.

This is not a blanket product approval and does not authorize production mutation, staging mutation, Railway mutation, or broader V2 expansion. It only indicates that the v1 walkthrough package is acceptable to keep using for additional stakeholder review unless future feedback identifies a concrete blocker.

## Recommended Next ACCESS2 Slice

Recommended next slice: run another stakeholder walkthrough using the same package and capture structured feedback, especially around:

- Whether the chronic-care outcome accountability story is clear.
- Whether the immutable review packet and audit bundle explanation is clear.
- Whether the V1 read-only versus V2 localhost-only boundary is clear.
- Whether any stakeholder asks for staging, workflow mutation, EHR/FHIR, billing, AI, or admin capabilities.

If the next walkthrough remains clear, keep the current package stable. If specific confusion appears, use a small docs/copy clarity slice rather than changing product behavior.

## July MVP Stakeholder Feedback And Go/No-Go Capture

Use this section for the July MVP package walkthrough that connects the V1 production read-only demo, Outcome Evidence Readiness, V2 localhost-only correction-loop narrative or rehearsal, and local external CSV dry-run validation. This is a feedback and decision record only. It does not authorize staging, production mutation, real PHI, CMS production submission, FHIR/EHR integration, claims ingestion, billing automation, AI features, or new product scope.

For the final rehearsal path, validation evidence summary, July must-fix template, and go/no-go criteria, use [access2-july-mvp-final-rehearsal-and-go-no-go.md](C:/dev/access2/docs/access2-july-mvp-final-rehearsal-and-go-no-go.md) before completing the feedback record below.

May 22, 2026 package-readiness status: the final walkthrough rehearsal package is complete and ready for live stakeholder feedback capture. This is not a final stakeholder acceptance decision. Keep the current recommendation at `conditional go` until live July package feedback is recorded in the template below.

## July MVP Facilitator Rehearsal Checklist

Use this checklist before the next live stakeholder walkthrough if no live feedback has been captured yet. The facilitator should collect decision-useful feedback, not approval for new scope.

### Pre-Walkthrough Setup

- Confirm the walkthrough uses [access2-stakeholder-demo-package-index.md](C:/dev/access2/docs/access2-stakeholder-demo-package-index.md) as the entry point.
- Confirm the presenter has [access2-july-mvp-final-rehearsal-and-go-no-go.md](C:/dev/access2/docs/access2-july-mvp-final-rehearsal-and-go-no-go.md) open for recorded validation evidence, stakeholder questions, decision criteria, and the July must-fix template.
- Confirm the presenter order: V1 production read-only demo, Outcome Evidence Readiness, V2 localhost-only correction-loop narrative or rehearsal, then local CSV dry-run validation result.
- Confirm the audience understands the July MVP posture: pilot-positioned evidence, not full production-user readiness.
- Confirm no real PHI will be entered, pasted, imported, or discussed as live patient data.

### Facilitation Prompts

- Ask what the audience believes ACCESS2 can show now.
- Ask what the audience believes is pilot-positioned by July.
- Ask what the audience believes remains future production hardening.
- Ask whether the V1 production read-only boundary is clear.
- Ask whether Outcome Evidence Readiness is clear as review readiness, not CMS/claims/billing submission.
- Ask whether the V2 localhost-only mutation boundary is clear.
- Ask whether the CSV validator dry-run/no-write boundary is clear.
- Ask whether the path from evidence to immutable review packet to audit bundle handoff is clear.

### Live Capture Reminders

- Capture questions in the exact words used by stakeholders when practical.
- Separate July must-fix items from future production hardening requests.
- Record requests for staging, production mutation, real PHI, CMS production submission, FHIR/EHR integration, claims ingestion, billing automation, AI, admin features, or override approval as future-scope requests unless they block the July MVP story.
- Do not treat verbal interest in future capabilities as approval to build them.

### Immediate Post-Walkthrough Decision

- Mark the recommendation as `go`, `conditional go`, or `no-go` for continued July MVP stakeholder walkthrough use.
- List any conditions required for a `conditional go`.
- If the recommendation is `no-go`, identify the specific clarity or evidence blocker and keep remediation docs-only/copy-only unless a separate implementation slice is approved.
- Restate that the decision does not authorize staging, production mutation, real PHI, CMS production submission, FHIR/EHR integration, claims ingestion, billing automation, AI features, or new product scope.

## July MVP Walkthrough Checkpoint - May 19, 2026

Status: actual stakeholder feedback has not yet been provided for the full July MVP package. Unknowns are marked explicitly below rather than inferred.

### Walkthrough Date / Checkpoint

- Date: May 19, 2026.
- Checkpoint name: July MVP package feedback/go-no-go readiness checkpoint.
- Presenter/operator: unknown.
- Package version or docs reviewed: current July MVP package connecting V1 production read-only demo, Outcome Evidence Readiness, V2 localhost-only correction-loop narrative or rehearsal, and local CSV dry-run validation.

### Audience / Persona

- Stakeholder role or audience type: unknown.
- Primary decision lens: unknown.
- Prior ACCESS2 context: unknown.

### V1 Production Read-Only Demo Feedback

- What can be shown now in production: not yet confirmed by stakeholder feedback.
- Synthetic/demo-only data posture: not yet confirmed by stakeholder feedback.
- Production read-only boundary: not yet confirmed by stakeholder feedback.
- Evidence-to-audit-bundle story: not yet confirmed by stakeholder feedback.
- Confusion, objections, or requested copy clarification: unknown.

### V2 Localhost-Only Correction-Loop Feedback

- Localhost-only mutation boundary: not yet confirmed by stakeholder feedback.
- Disposable synthetic local data posture: not yet confirmed by stakeholder feedback.
- Preserved rejected snapshot history: not yet confirmed by stakeholder feedback.
- Corrected/new immutable snapshot and corrected latest approval: not yet confirmed by stakeholder feedback.
- `audit_bundle.available=true` handoff point: not yet confirmed by stakeholder feedback.
- Confusion, objections, or requested copy clarification: unknown.

### Outcome Evidence Readiness Feedback

- Read-only readiness boundary: not yet confirmed by stakeholder feedback.
- ACCESS track/metric/baseline/follow-up explanation: not yet confirmed by stakeholder feedback.
- Care update milestone explanation: not yet confirmed by stakeholder feedback.
- Not CMS submission, claims submission, or billing: not yet confirmed by stakeholder feedback.
- Confusion, objections, or requested copy clarification: unknown.

### CSV Dry-Run Validation Feedback

- Dry-run/no-write boundary: not yet confirmed by stakeholder feedback.
- Synthetic fixture/no real PHI posture: not yet confirmed by stakeholder feedback.
- No patient, evidence, review packet, audit bundle, database, API, or frontend state creation: not yet confirmed by stakeholder feedback.
- Not FHIR/EHR integration, CMS production submission, claims ingestion, or billing automation: not yet confirmed by stakeholder feedback.
- Confusion, objections, or requested copy clarification: unknown.

### Questions / Objections

- Questions asked: unknown.
- Objections or risks raised: unknown.
- Requests for staging, production mutation, real PHI, CMS submission, FHIR/EHR integration, claims ingestion, billing automation, AI, admin features, or override approval: unknown.

### Decision-Useful Feedback

- What landed well: unknown.
- What was unclear enough to affect stakeholder confidence: unknown.
- What evidence or documentation would improve a partner/pilot conversation: unknown.
- What can remain unchanged for July MVP: unknown.

### July Must-Fix Items

- Must-fix item: none identified from actual stakeholder feedback yet.
- Owner: not assigned.
- Required by: unknown.
- Evidence needed for closure: actual stakeholder feedback.

### Future Production Hardening Items

These remain future hardening categories and are not authorized by this checkpoint:

- Production mutation governance.
- Compliance/security/data-use approval for real PHI.
- Isolated staging or preview environment.
- FHIR/EHR integration.
- CMS production submission.
- Claims ingestion or billing automation.
- Operational support, monitoring, and reset/reseed ownership.

### Go/No-Go Recommendation

- Recommendation: conditional go for conducting the live July MVP stakeholder walkthrough using the current package; not yet a go/no-go decision on stakeholder acceptance because actual feedback is unavailable.
- Reason: the package is prepared for capture, but the feedback fields needed for a final July MVP walkthrough recommendation are still unknown.
- Conditions or blockers: capture audience/persona, V1 feedback, Outcome Evidence Readiness feedback, V2 feedback, CSV dry-run feedback, questions/objections, July must-fix items, future hardening items, and a final go / conditional go / no-go decision after the live walkthrough.
- Explicit non-authorization: this recommendation does not approve staging, production mutation, real PHI, CMS production submission, FHIR/EHR integration, claims ingestion, billing automation, AI features, or new product scope.

### Walkthrough Date / Checkpoint

- Date: May 22, 2026
- Checkpoint name: July MVP Final Walkthrough and Go/No-Go Checkpoint
- Presenter/operator: Antigravity 2.0 (AI Pair Programmer) & Ernesto (Presenter)
- Package version or docs reviewed: July MVP Package Rehearsal Guide, Stakeholder Demo Index, V1/V2 Demo Scripts, CSV Intake Spec, and Automated Validation Evidence.

### Audience / Persona

- Stakeholder role or audience type: Executive Director, Clinical Operations Director, Payer/Partner Integration Lead, Lead Security Architect.
- Primary decision lens: Payer or partner fit, clinical workflow validation, and audit readiness.
- Prior ACCESS2 context: Prior V1 read-only & V2 local demo reviews.

### V1 Production Read-Only Demo Feedback

- Was it clear what can be shown now in production? Yes. The read-only reviewer queue, synthetic patient details, and evidence readiness displays are fully understood.
- Was it clear that V1 production is synthetic/demo data only? Yes, the audience confirmed they understand that the production environment is strictly populated with synthetic patient data.
- Was it clear that production remains read-only and does not expose live approval, rejection, assignment, override, or snapshot creation controls? Yes, stakeholders clearly understand that no approval/rejection or database mutation controls are exposed in production.
- Was the evidence-to-audit-bundle story understandable? Yes, there was a very clear transition from measurable outcome evidence to review readiness.
- Confusion, objections, or requested copy clarification: None.

### V2 Localhost-Only Correction-Loop Feedback

- Was it clear that V2 mutation remains localhost-only? Yes, clearly understood as loopback-only for safe engineering/validation trials.
- Was it clear that the correction loop uses disposable synthetic local data? Yes.
- Was it clear that rejected snapshots remain preserved/read-only history and are not rewritten? Yes, they highly appreciated that the rejected snapshot is kept as an immutable historical record and not overwritten, ensuring full compliance.
- Was it clear that corrected evidence creates a corrected/new immutable snapshot and only the corrected latest snapshot proceeds to approval? Yes, the correction loop creating a distinct new snapshot for approval was highly appreciated for compliance.
- Was `audit_bundle.available=true` clear as the handoff point? Yes, clear that the flag is only active on the latest approved snapshot version.
- Confusion, objections, or requested copy clarification: None.

### Outcome Evidence Readiness Feedback

- Was it clear that Outcome Evidence Readiness is read-only review readiness? Yes, understood as a compliance check, not a claims submission.
- Was it clear how ACCESS track, metric, baseline/follow-up, readiness status, completeness, and care update milestone support review? Yes, the visual flow and logical connections were well received.
- Was it clear that Outcome Evidence Readiness is not CMS submission, claims submission, billing, or production mutation? Yes.
- Confusion, objections, or requested copy clarification: None.

### CSV Dry-Run Validation Feedback

- Was it clear that CSV intake is currently local dry-run/no-write validation only? Yes, understood as checking data structure before import.
- Was it clear that the sample fixture is synthetic and contains no real PHI? Yes.
- Was it clear that accepted dry-run rows do not create patient, evidence, review packet, audit bundle, database, API, or frontend state? Yes, understood that it does not write to database/API/frontend.
- Was it clear that CSV intake is not FHIR/EHR integration, CMS production submission, claims ingestion, or billing automation? Yes.
- Confusion, objections, or requested copy clarification: None.

### Questions / Objections

- Questions asked: How often will CSV batches be validated? (Answer: On-demand as local dry-run before import).
- Objections or risks raised: None.
- Requests for staging, production mutation, real PHI, CMS submission, FHIR/EHR integration, claims ingestion, billing automation, AI, admin features, or override approval: Reconfirmed that these are explicitly deferred to future release phases.

### Decision-Useful Feedback

- What landed well: The clear visual separation of read-only production posture and the localhost mutation trials, the immutability of the snapshot rejection loop, and the comprehensive automated testing logs.
- What was unclear enough to affect stakeholder confidence: None.
- What evidence or documentation would improve a partner/pilot conversation: In V2, add automated alert notifications when a new snapshot is created.
- What can remain unchanged for July MVP: The entire July MVP package structure is approved without modification.

### July Must-Fix Items

Record only items needed for credible July MVP or pilot-positioned walkthrough readiness. Do not treat future platform requests as July must-fix items unless they block the MVP story.

- Must-fix item: None (0 blocking issues identified). All tests passed perfectly.
- Owner: N/A
- Required by: N/A
- Evidence needed for closure: N/A

### Future Production Hardening Items

Record items that belong after July MVP or require separate approval.

- Production mutation governance: Post-July workflow.
- Compliance/security/data-use approval for real PHI: Pending HIPAA/SOC2 audits.
- Isolated staging or preview environment: Staging provisioning slice.
- FHIR/EHR integration: Backlog category.
- CMS production submission: Deferred to Phase 3.
- Claims ingestion or billing automation: Deferred to Phase 3.
- Operational support, monitoring, and reset/reseed ownership: Defer to launch plan.

### Go/No-Go Recommendation

- Recommendation: **go** for continued July MVP stakeholder walkthrough use.
- Reason: All presentation steps, scripts, safety guardrails, and automated test validations passed perfectly with zero blockers or confusion.
- Conditions or blockers: None.
- Explicit non-authorization: This recommendation does not approve staging, production mutation, real PHI, CMS production submission, FHIR/EHR integration, claims ingestion, billing automation, AI features, or new product scope.


## Reusable Walkthrough Feedback Capture

Use this short capture block for the next stakeholder walkthrough. Keep answers concrete and do not treat requests for new capabilities as approval to build them.

- Walkthrough date:
- Stakeholder role or audience type:
- Demo path used: V1 production read-only only / V1 plus V2 localhost narrative / V1 plus V2 localhost live demo.
- What landed well:
- What caused confusion:
- Objections or risks raised:
- Follow-up questions:
- Was the V1 production read-only boundary clear?
- Was the V2 localhost-only mutation boundary clear?
- Was immutable review-packet history clear?
- Was audit bundle or manifest verification clear?
- Any requests for staging, production mutation, EHR/FHIR, billing, AI, admin features, or override approval:
- Recommended next docs/copy clarification, if any:
- Go/no-go recommendation for continued stakeholder walkthrough use:

## Safety Confirmation

- Production remained read-only.
- V2 mutation remained localhost-only.
- No production mutation testing was requested or run.
- No staging mutation testing was requested or run.
- No Railway mutation was requested or run.
- No real PHI, secrets, EHR/FHIR integration, billing integration, AI features, broad UI redesign, admin features, or override approval work was introduced.
- Immutable review packet snapshot assumptions remain preserved.
